Clearly, outcomes of interventional trials could be misleading if diagnostic tools fail to distinguish between uraemia and depressive symptoms. Likewise, an excess “placebo effect” was not responsible for masking the effect of sertraline, as the improvements among study participants receiving placebo were lower than those typically reported in antidepressant studies.“We are beginning to wrestle with the reality that these psychiatric disorders have many subtypes,” said Trivedi.
One other RCT of escitalopram versus placebo in 62 patients on haemodialysis provided no efficacy data. Applies to: Renal DysfunctionSertraline is primarily metabolized by the liver. Your kidneys filter wastes and excess fluids from your blood, which are then excreted in your urine. Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.Moderate Potential Hazard, Moderate plausibility. These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.

Skip the missed dose if it is almost time for your next scheduled dose. The information is provided as a guide. Follow all directions on your prescription label. Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder. Learn about side effects, warnings, dosage, and more. ■ To make sure you get the entire dose, add a little more water to the same glass, swirl gently and drink right away.Zoloft can cause you to have a false positive drug screening test. Applies to: Liver DiseaseSelective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver. You have entered an invalid code Hoddesdon, Hertfortshire, UK: Merck Sharp & Dohme Limited, 2010Federaal Agentschap voor Geneesmiddelen en GezondheidsproductenMarked effect of liver and kidney function on the pharmacokinetics of selegilineFluoxetine kinetics and protein binding in normal and impaired renal functionSteady-state pharmacokinetics of nefazodone in subjects with normal and impaired renal functionSingle-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairmentMirtazapine oral single dose kinetics in patients with different degrees of renal failureA comparative study of trazodone serum concentrations in patients with normal or impaired renal functionPharmacokinetics of single-dose reboxetine in volunteers with renal insufficiencyThe pharmacokinetics of nortriptyline in patients with chronic renal failureNortriptyline metabolism in chronic renal failure: metabolite elimination[Comparative study of the pharmacokinetics of amitriptyline oxide and trimipramine after single administration in healthy male probands and patients with renal failure]The pharmacokinetics of paroxetine in renal impairmentHemodialysis of doxepin and desmethyldoxepin in uremic patientsSingle-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjectsFluoxetine: clinical pharmacology and physiologic dispositionTricyclic antidepressant and metabolite levels in chronic renal failureComparison of the serum protein binding of maprotiline and phenytoin in uraemic patients on haemodialysisPharmacokinetics of milnacipran in renal impairmentPharmacokinetic and metabolic parameters of tianeptine in healthy volunteers and in populations with risk factorsTianeptine and its main metabolite. Longer follow-up would be needed to demonstrate a sustained benefit of pharmacologic treatment and evaluate whether hard end-points such as hospitalization and mortality are affected without too many side-effects.
We reported these results as a mean difference and 95% confidence interval when possible.